Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Stowasser

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Respiratory Medicine|August 13, 2019
Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanibLuca Richeldi, Bruno Crestani, Arata Azuma, et al.
Thorax|September 28, 2016
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volumeMartin Kolb, Luca Richeldi, Jürgen Behr, et al.
Respirology (Carlton, Vic.)|August 30, 2023
Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosisToby M Maher, Susanne Stowasser, Florian Voss, et al.
The New England Journal of Medicine|September 18, 2018
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary FibrosisMartin Kolb, Ganesh Raghu, Athol U Wells, et al.
Respiratory Medicine|February 27, 2016
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trialsLuca Richeldi, Vincent Cottin, Roland M du Bois, et al.
ACR Open Rheumatology|July 19, 2022
Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled TrialShervin Assassi, Oliver Distler, Yannick Allanore, et al.
Respiration; International Review of Thoracic Diseases|February 8, 2018
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary FibrosisMichael Kreuter, Ulrich Costabel, Luca Richeldi, et al.
ERJ Open Research|March 18, 2026
Design of a phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosisWim A Wuyts, Francesco Bonella, Haruyuki Ishii, et al.
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
The European Respiratory Journal|July 10, 2019
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseasesLutz Wollin, Jörg H W Distler, Elizabeth F Redente, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Respiratory Medicine|August 13, 2019
Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanibLuca Richeldi, Bruno Crestani, Arata Azuma, et al.
Thorax|September 28, 2016
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volumeMartin Kolb, Luca Richeldi, Jürgen Behr, et al.
Respirology (Carlton, Vic.)|August 30, 2023
Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosisToby M Maher, Susanne Stowasser, Florian Voss, et al.
The New England Journal of Medicine|September 18, 2018
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary FibrosisMartin Kolb, Ganesh Raghu, Athol U Wells, et al.
Respiratory Medicine|February 27, 2016
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trialsLuca Richeldi, Vincent Cottin, Roland M du Bois, et al.
ACR Open Rheumatology|July 19, 2022
Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled TrialShervin Assassi, Oliver Distler, Yannick Allanore, et al.
Respiration; International Review of Thoracic Diseases|February 8, 2018
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary FibrosisMichael Kreuter, Ulrich Costabel, Luca Richeldi, et al.
ERJ Open Research|March 18, 2026
Design of a phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosisWim A Wuyts, Francesco Bonella, Haruyuki Ishii, et al.
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
The European Respiratory Journal|July 10, 2019
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseasesLutz Wollin, Jörg H W Distler, Elizabeth F Redente, et al.
Pageof 7